- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06700447
Proteção contra a desinformação sobre vacinas contra o HIV entre meninas adolescentes e mulheres jovens na África do Sul (PROTECT)
Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes. The ongoing susceptibility of young women to HIV infection and the sub-optimal uptake of prevention options such as Pre-Exposure Prophylaxis (PrEP) that are highly effective creates a need for an HIV vaccine to benefit populations at substantial risk of HIV infection. However, lessons from previous vaccine studies and the recent COVID-19 vaccine have highlighted significant barriers to vaccine uptake, such as widespread misinformation and vaccine hesitancy. These challenges threaten the successful implementation of a future HIV vaccine. Building on these insights, this study will utilise psychological inoculation theory to develop and evaluate HIV vaccine messages among adolescent girls and young women. Primary objective: To compare changes in intentions to receive HIV vaccine following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.
Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about the HIV vaccine in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Johannesburg, África do Sul
- Health Economics and Epidemiology Research Office, University of the Witwatersrand
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Female
- Age 18-29 years
- Self-reported history of sexual activity in the past 12 months
- Self-reported HIV-negative status or unknown HIV status at enrolment
- Willing and able to provide written informed consent
- Able to read and understand English
Exclusion Criteria:
- Unwilling or unable to provide consent for study participation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Control
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study. |
Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study. |
|
Outro: Enhanced inoculation message
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
HIV Vaccine Intention, at the End of the Baseline Assessment
Prazo: At the end of the baseline assessment
|
Intention to get the HIV vaccine, measured after inoculation intervention and misinformation exposure The intention to get the vaccine will be measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine. |
At the end of the baseline assessment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
HIV Vaccine Intention, Follow-up
Prazo: 2-4 weeks
|
Intention to get the HIV vaccine, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine. |
2-4 weeks
|
|
Recommend to Friends, at the End of the Baseline Assessment
Prazo: At the end of the baseline assessment
|
Intention to recommend the HIV vaccine to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend. |
At the end of the baseline assessment
|
|
Recommend to Friends, Follow-up
Prazo: 2-4 weeks
|
Intention to recommend the HIV vaccine to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #1
Prazo: At the end of the baseline assessment
|
Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #2
Prazo: At the end of the baseline assessment
|
Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #3
Prazo: At the end of the baseline assessment
|
Extent to which claim #3 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #4
Prazo: At the end of the baseline assessment
|
Extent to which claim #4 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #5
Prazo: At the end of the baseline assessment
|
Extent to which claim #5 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #6
Prazo: At the end of the baseline assessment
|
Extent to which claim #6 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #1
Prazo: At the end of the baseline assessment
|
Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #2
Prazo: At the end of the baseline assessment
|
Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #3
Prazo: At the end of the baseline assessment
|
Extent to which claim #3 made the participants anxious or nervous about the HIV vaccine. TThey were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #4
Prazo: At the end of the baseline assessment
|
Extent to which claim #4 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #5
Prazo: At the end of the baseline assessment
|
Extent to which claim #5 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #6
Prazo: At the end of the baseline assessment
|
Extent to which claim #6 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #1
Prazo: At the end of the baseline assessment
|
Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #7
Prazo: At the end of the baseline assessment
|
Extent to which claim #7 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #3
Prazo: At the end of the baseline assessment
|
Extent to which claim #3 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #4
Prazo: At the end of the baseline assessment
|
Extent to which claim #4 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #5
Prazo: At the end of the baseline assessment
|
Extent to which claim #5 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #6
Prazo: At the end of the baseline assessment
|
Extent to which claim #6 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Credibility of Inoculated Exposure #1, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #2, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Shareability of Inoculated Exposure #1, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of Inoculated Exposure #2, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Anxiousness of Inoculated Exposure #1, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of Inoculated Exposure #2, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #12, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #12 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #8, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #8 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #9, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #9 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #10, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #10 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Credibility of New Claims, Exposure #11, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #11 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Anxiousness o of New Claims, Exposure #12, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #12 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Claim #8, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #8 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #9, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #9 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #10, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #10 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #11, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #11 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #12, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #12 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #8, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #8 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #9, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #9 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #10, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #10 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #11, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #11 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
|
Credibility of Inoculated Exposure #7
Prazo: At the end of the baseline assessment
|
Extent to which claim #7 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
At the end of the baseline assessment
|
|
Anxiousness of Inoculated Exposure #7
Prazo: At the end of the baseline assessment
|
Extent to which claim #7 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
At the end of the baseline assessment
|
|
Shareability of Inoculated Exposure #2
Prazo: At the end of the baseline assessment
|
Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
At the end of the baseline assessment
|
|
Credibility of New Claims, Exposure #13, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #13 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim. |
2-4 weeks
|
|
Anxiousness of New Claims, Exposure #13, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #13 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness. |
2-4 weeks
|
|
Shareability of New Claims, Exposure #13, Follow-up
Prazo: 2-4 weeks
|
Extent to which claim #13 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim. |
2-4 weeks
|
Colaboradores e Investigadores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1R01MH132401 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The investigators are still determining the data sharing plan and if we will be sharing IPD yet
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .